Skip to main content
. Author manuscript; available in PMC: 2020 Apr 23.
Published in final edited form as: J Pharmacokinet Pharmacodyn. 2019 Mar 25;46(2):155–163. doi: 10.1007/s10928-019-09626-7

Table 4.

Ratios of Altered Condition/Control following Oral Dosing of Midazolam, an Intermediate ERH CYP3A Substrate, when Inhibited by Itraconazole and Induced by Rifampin [13].

AUC Ratio t½ Ratio Cmax,1st dose Ratio
Inhibited 6.75 3.06 3.12
Control
Induced 0.023 0.372 0.054
Control